ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Assess Chelation Therapy (TACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00044213
Recruitment Status : Completed
First Posted : August 23, 2002
Results First Posted : November 5, 2013
Last Update Posted : November 5, 2013
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Gervasio Lamas, MD, Mt. Sinai Medical Center, Miami

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Coronary Artery Disease
Interventions: Drug: EDTA
Drug: EDTA Placebo
Dietary Supplement: High Dose Vitamin
Dietary Supplement: High Dose Vitamin Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The primary analysis of the trial included 1708 patients who had been enrolled from September 2003 through October 2011 (median, 55 months)Participants were recruited at 134 sites in the US and Canada.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Participant Flow:   Overall Study
    EDTA + High Dose Vitamin   EDTA + High Dose Vitamin Placebo   EDTA Placebo + High Dose Vitamin   EDTA Placebo + High Dose Vitamin Placebo
STARTED   421   418   432   437 
COMPLETED   321   306   294   301 
NOT COMPLETED   100   112   138   136 
Withdrawal by Subject                50                65                91                83 
Death                42                42                42                49 
Lost to Follow-up                8                5                5                4 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
Total Total of all reporting groups

Baseline Measures
   EDTA + High Dose Vitamin   EDTA + High Dose Vitamin Placebo   EDTA Placebo + High Dose Vitamin   EDTA Placebo + High Dose Vitamin Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 421   418   432   437   1708 
Age 
[Units: Years]
Mean (Full Range) 		 65 
 (59 to 71)  		 65 
 (60 to 72)  		 66 
 (59 to 72)  		 66 
 (59 to 72)  		 65.5 
 (59 to 72) 
Gender 
[Units: Participants]
 		         
Female   70   82   77   70   299 
Male   351   336   355   367   1409 


  Outcome Measures

1.  Primary:   A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.   [ Time Frame: Measured over a maximum 5-year follow-up period- 55 month median ]

Measure Type Primary
Measure Title A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.
Measure Description Number of patients with events (composite of death from any cause, MI, stroke, coronary revascularization or hospitalization for angina) Events were centrally adjudicated where available; otherwise site reported events were used.
Time Frame Measured over a maximum 5-year follow-up period- 55 month median  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Measured Values
   EDTA + High Dose Vitamin   EDTA + High Dose Vitamin Placebo   EDTA Placebo + High Dose Vitamin   EDTA Placebo + High Dose Vitamin Placebo 
Participants Analyzed 
[Units: Participants]
 		 421   418   432   437 
A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina. 
[Units: Participants]
 		 108   114   122   139 

No statistical analysis provided for A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.



2.  Secondary:   A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.   [ Time Frame: Measured over a maximum 5-year follow-up period- 55 month median ]

Measure Type Secondary
Measure Title A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.
Measure Description Number of patients with events (composite of cardiovascular death, non-fatal MI, non-fatal stroke) Events were centrally adjudicated where available; otherwise site reported events were used.
Time Frame Measured over a maximum 5-year follow-up period- 55 month median  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Measured Values
   EDTA + High Dose Vitamin   EDTA + High Dose Vitamin Placebo   EDTA Placebo + High Dose Vitamin   EDTA Placebo + High Dose Vitamin Placebo 
Participants Analyzed 
[Units: Participants]
 		 421   418   432   437 
A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke. 
[Units: Participants]
 		 39   57   55   58 

No statistical analysis provided for A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.




  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information